LloydsPharmacy parent company Celesio UK's managing director Cormac Tobin is stepping down with immediate effect, the multiple has announced.
Mr Tobin has been with the company for more than a decade, and was appointed its managing director in 2013. Celesio UK is currently looking for his successor, the company announced today (2 November).
In the meantime, the company will be headed up by the remaining members of the Celesio UK management board, who will report to Brian Tyler, chairman of the McKesson Europe's management board.
Related Article: Nearly twice as many patients in deprived areas prescribed dependency-forming meds
LloydsPharmacy made headlines last week after it announced that it would close 190 of its branches due to funding cuts and other financial clawbacks.
'Energetic and trusted leader'
Responding to the news, Mr Tyler said: 'Cormac has been an energetic and trusted leader of our UK and Ireland businesses. He has built a strong leadership team for Celesio UK and his warm and engaging personality made him many friends across community pharmacy and beyond.
'There is a genuine affection for him amongst our colleagues who value his ability to understand customers and patients and put them at the heart of everything we do.
Related Article: Finding sustainable funding solution is ‘matter of urgency’ for government
'I am grateful for the dedication that Cormac has shown over the last few years and his leadership through an ever-changing external environment. I wish him every success for the future.'
He continued: 'There is a strong and experienced management team in the UK consisting of Nigel Swift, Hilary Stables, Ruth Poole, Catherine McDermott and Marcus Hilger. Together with the entire business in the UK, this leadership team will be able to successfully navigate current and future challenges that the company faces.'
More on LloydsPharmacy:
Related Article: NICE recommends ‘game changer’ wearable tech for type 1 diabetes
190 LloydsPharmacy branches to close
Opinion: Even the multiples haven’t managed to dodge the brutal effects of the cuts
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.